Ford Motor Co
Change company Symbol lookup
Select an option...
F Ford Motor Co
BA Boeing Co
GILD Gilead Sciences Inc
CWBR CohBar Inc
TSLA Tesla Inc
WEC WEC Energy Group Inc
PFE Pfizer Inc
T AT&T Inc
BFC Bank First Corp
RIGMF Ridgestone Mining Inc
Go

Consumer Discretionary : Automobiles | Mid Cap Value
Company profile

Ford Motor Company is a global automotive and mobility company. The Company's business includes designing, manufacturing, marketing, and servicing a full line of Ford cars, trucks, and sport utility vehicles (SUVs), as well as Lincoln luxury vehicles. The Company operates in four segments: Automotive, Financial Services, Ford Smart Mobility LLC, and Central Treasury Operations. The Automotive segment primarily includes the sale of Ford and Lincoln brand vehicles, service parts, and accessories across the world. The Financial Services segment primarily includes its vehicle-related financing and leasing activities at Ford Motor Credit Company LLC. Ford Smart Mobility LLC is a subsidiary formed to design, build, grow, and invest in emerging mobility services. The Central Treasury Operations segment is primarily engaged in decision making for investments, risk management activities, and providing financing for the Automotive segment.

Closing Price
$6.05
Day's Change
0.07 (1.17%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.17
Day's Low
6.00
Volume
(Below Average)
Volume:
67,270,506

10-day average volume:
78,477,635
67,270,506

FDA issues rules for coronavirus vaccine developers

12:41 pm ET June 30, 2020 (MarketWatch)
Print

The Food and Drug Administration (FDA) issued new rules on Tuesday for the companies developing COVID-19 vaccines. "While the FDA is committed to help expedite this work, we will not cut corners in our decision making, and we're making clear in our guidance what are the data that we need, that should be submitted, to meet our regulatory standards of approval," FDA commissioner Dr. Stephen Hahn said Tuesday during a Senate committee hearing. The guidance (https://www.fda.gov/media/139638/download) states that the primary efficacy endpoint in a placebo-controlled efficacy clinical trial should be at least 50%, meaning the vaccine needs "to reduce the risk of disease caused by COVID-19 by 50%" when compared to the placebo, according to Brad Loncar, a longtime biotech investor and CEO of Loncar Investments. There are a number of drugmakers developing COVID-19 vaccine candidates including AstraZeneca (AZN.LN) and the University of Oxford, Inovio Pharmaceuticals Inc. (INO), and Moderna Inc. (MRNA), two of which (Inovio and Moderna) have disclosed preliminary data from their Phase 1 trials. A return to economic normalcy has largely been tied to the arrival of vaccines that can prevent infections from the coronavirus. "There is no guarantee...that we will have a safe and effective vaccine, but we are cautiously optimistic," Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, testified during the same hearing.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

June 30, 2020 12:41 ET (16:41 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.